Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03454243 · ClinicalTrials.gov registry record · Early Phase 1
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
A Early Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT03454243 is a Early Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 1 participants.
The verdict
NCT03454243, a Early Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit. This study will examine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of RXDX 106.
Interventions
- DRUG RXDX-106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2018-06-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03454243
The ClinicalTrials.gov registry entry for NCT03454243 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RXDX-106 is the first listed.
NCT03454243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03454243 about?
NCT03454243 is a clinical study titled "Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors". This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit. This study will examine the safety, tolerability, pharmacokinetics (PK), pharmacodynami...
What is the current status of trial NCT03454243?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2018-02-15. Estimated completion is 2018-06-05.
What interventions are being tested in trial NCT03454243?
The interventions under investigation include: RXDX-106 (DRUG).
Who is sponsoring clinical trial NCT03454243?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.